Realizing an Integrated Healthcare Company
First written in FY2020-Q3. 6 of 10 entries say "Advanced", first in FY2021. Latest entry: 2026-05-14.
1 other company's latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「In the pharmaceutical business, we aim to achieve further growth, centered on Daiichi Sankyo Espha Co., Ltd. We will continue expanding our product lineup, focusing on authorized generic products. We will also use the pharmacy business's expertise in the information provided by medical representatives to deliver information from the perspective of patients and healthcare professionals and expand our market share.」
The company is expanding its pharmaceutical business, centered on Daiichi Sankyo Espha Co., Ltd., while expanding its authorized generic product lineup and market share by leveraging the pharmacy business's expertise. - FY2025-H1AdvancedAnnual report
「We will continue working to expand the profitability of the pharmaceutical business and pursue this together with the pharmacy and BPO businesses in order to make a leap forward as an integrated healthcare company.」
The company is pursuing growth in the profitability of its pharmaceutical business as an independent business area and is giving concrete form to its aim of becoming an integrated healthcare company together with its pharmacy and BPO businesses. - FY2024-Q3RestatedAnnual report
「We will continue working to expand the profitability of the healthcare-related business, including the pharmaceutical manufacturing and marketing business, and develop as a company that provides comprehensive healthcare services by combining it with our core insurance pharmacy business, thereby contributing to society through the collective strength of the Group.」
The company continues to pursue its goal of combining the healthcare-related business, including pharmaceutical manufacturing and marketing, with the insurance pharmacy business and developing into a company providing comprehensive healthcare services. - FY2024-Q1AdvancedAnnual report
「We will continue working to expand the profitability of the healthcare-related business, including the pharmaceutical manufacturing and marketing business, and develop as a company that provides comprehensive healthcare services by combining it with our core insurance pharmacy business, thereby contributing to society through the collective strength of the Group.」
The company has again specified its plan to combine the healthcare-related business, including pharmaceutical manufacturing and marketing, with the insurance pharmacy business and develop into a company providing comprehensive healthcare services. - FY2023-Q2RestatedAnnual report
「The company will celebrate its 30th anniversary this year. It has continued its business based on the belief in continuity of healthcare, aiming to operate community-based pharmacies. Going forward, under the group's corporate philosophy, “We are committed to the quality of life of everyone, anytime and anywhere, for you,” it will continue moving forward as a comprehensive healthcare company.」
The company continues to pursue its goal of advancing toward becoming an integrated healthcare company under its corporate philosophy. - FY2023-Q1RestatedAnnual report
「Going forward, under the Group’s corporate philosophy, “We are committed to the quality of life of everyone. Anytime, anywhere, for you,” we will continue advancing toward becoming an integrated healthcare company.」
The company continues to pursue its goal of advancing toward becoming an integrated healthcare company under its corporate philosophy. - FY2021AdvancedAnnual report
「In the healthcare-related business, the CSO business and pharmaceutical manufacturing and marketing business performed steadily. By expanding the healthcare-related business, a growth area, we will increase its share of operating profit and build a stable foundation for advancing toward becoming an integrated healthcare company.」
The company specified its policy of increasing the healthcare-related business’s share of operating profit through expansion and building a foundation for advancing toward becoming an integrated healthcare company. - FY2020-Q3First statedAnnual report
「Going forward, the group will enhance synergies among its 3 businesses, establish an end-to-end service spanning pharmaceutical manufacturing through delivery to patients, and pursue its goal of becoming a comprehensive healthcare company.」
The company outlined for the first time its goal of becoming an integrated healthcare company that provides end-to-end services from pharmaceutical manufacturing to delivery to patients by increasing synergies among its insurance pharmacy, BPO, and pharmaceutical manufacturing and marketing businesses.